WJNS  Vol.2 No.4 , November 2012
Vitamin E in ataxia and neurodegenerative diseases: A review
ABSTRACT
Vitamin E is one of the most important lipid-soluble antioxidants. It is essential for the neurological function but its role in the central nervous system has not fully been elucidated. It is known that tocopherol acts in protecting cell membranes from oxidative damage and it can act as an anti-in?ammatory agent, which may also be neuroprotective, as well as regulating speci?c enzymes. There is growing evidence that oxidative stress plays a key role in the pathophysiology of several neurodegenerative disorders. These diseases are defined by the progressive loss of speci?c neuronal cell populations and are associated with protein aggregates. We reviewed some aspects related to the role of antioxidant properties of Vitamin E in preventing and/or curing neurodegenerative disorders such as the Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis, ataxia, tardive dyskinesia and Huntington’s disease.

Cite this paper
Imounan, F. , Bouslam, N. , Aasfara, J. , El alaoui, K. , Regragui, W. , Benhaddou, E. , Bouhouche, A. , Benomar, A. and Yahyaoui, M. (2012) Vitamin E in ataxia and neurodegenerative diseases: A review. World Journal of Neuroscience, 2, 217-222. doi: 10.4236/wjns.2012.24033.
References
[1]   National Academy of Sciences (2000) Dietary reference intakes for Vitamin C, Vitamin E, selenium and carotenoids. National Academy Press, Washington DC.

[2]   Bjorneboe, A., Bjorneboe, G. and Drevon, C. (1990) Absorption, transport and distribution of Vitamin E. Journal of Nutrition, 120, 233-242.

[3]   Ford, E.S. and Sowell, A. (1999) Serum Alpha-tocopherol status in the United States population: Findings from the third national health and nutrition examination survey. American Journal of Epidemiology, 150, 290-300. doi:10.1093/oxfordjournals.aje.a010001

[4]   Sokol, R.J. (1988) Vitamin E deficiency and neurologic disease. Annual Review of Nutrition, 8, 351-373.

[5]   Aparicio, J.M., et al. (2001) Ataxia with isolated Vitamin E deficiency: Case report and review of the literature. Journal of Pediatric Gastroenterology and Nutrition, 33, 206-210. doi:10.1097/00005176-200108000-00022

[6]   Sokol, R.J., et al. (1985) Vitamin E deficiency in adults with chronic liver disease. The American Journal of Clinical Nutrition, 41, 66-72.

[7]   Sokol, R.J. (1988) Vitamin E deficiency and neurologic disease. Annual Review of Nutrition, 8, 351-373. doi:10.1146/annurev.nu.08.070188.002031

[8]   Victor, M. and Ropper, A.H. (2005) Disorders due to deficiencies of fat-soluble Vitamins. 7th Edition, McGraw-Hill, New York.

[9]   Ziegner, U.H., et al. (2002) Progressive neurodegeneration in patients with primary immunodeficiency disease on IVIG treatment. Clinical Immunology, 102, 19-24. doi:10.1006/clim.2001.5140

[10]   Aslam, A., Misbah, S.A., Talbot, K. and Chapela, H. (2004) Vitamin E deficiency induced neurological disease in common variable immunodeficiency: Two cases and a review of the literature of Vitamin E deficiency. Clinical Immunology, 112, 24-29. doi:10.1016/j.clim.2004.02.001

[11]   Sokol, R.J. (1988) Vitamin E deficiency and neurologic disease. Annual Review of Nutrition, 8, 351-373. doi:10.1146/annurev.nu.08.070188.002031

[12]   Weber, P., Bendich, A. and Machlin, L.J. (1997) Vitamin E and human health: Rationale for determining recommended intake levels. Nutrition, 13, 450-460. doi:10.1016/S0899-9007(97)00110-X

[13]   Kappus, H. and Diplock, A.T. (1992) Tolerance and safety of Vitamin E: A toxicological position report. Free Radical Biology & Medicine, 13, 55-74. doi:10.1016/0891-5849(92)90166-E

[14]   Ricciarelli, R., Argellati, F., Pronzato, M.A., et al. (2007) Vitamin E and neurodegenerative diseases. Molecular Aspects of Medicine 28, 591-606. doi:10.1016/j.mam.2007.01.004

[15]   Practice Guidelines Cover (1997) Management of Alzheimer’s disease. American Journal of Health-System Pharmacy, 54, 1481-1485.

[16]   Grundman, M. (2000) Vitamin E and alzheimer disease: The basis for additional clinical trials. The American Journal of Clinical Nutrition, 71, S630- S636.

[17]   Weber, C.A. and Ernst, M.E. (2006) Antioxidants, sup- plements, and Parkinson’s disease. The Annals of Pharmacotherapy, 40, 935-938. doi:10.1345/aph.1G551

[18]   Parkinson Study Group (1989) Datatop: A multicenter controlled clinical trial in early Parkinson’s disease. Archives of Neurology, 46, 1052-1060. doi:10.1001/archneur.1989.00520460028009

[19]   Parkinson Study Group (1993) Effects of tocopherol and deprenyl on the progression of disability in early Parkinson’s disease. The New England Journal of Medicine, 328, 176-183. doi:10.1056/NEJM199301213280305

[20]   Ricciarelli, R., Argellati, F. and Cinzia Domenicotti, M.A. (2007) Vitamin E and neurodegenerative diseases: Review. Molecular Aspects of Medicine, 28, 591-606. doi:10.1016/j.mam.2007.01.004

[21]   Graf, M., et al. (2005) High dose Vitamin E therapy in amyotrophic laterals sclerosis as add-on therapy to riluzole: Results of a placebo-controlled double-blind study. Journal of Neural Transmission, 112, 649-660. doi:10.1007/s00702-004-0220-1

[22]   Nelson, L.M., Matkin, C., Longstreth, Jr., et al. (2000) Population-based case-control study of amyotrophic lateral sclerosis in western Washington State. II. Diet. American Journal of Epidemiology, 151, 164-173. doi:10.1093/oxfordjournals.aje.a010184

[23]   Aparicio, J.M., Quintana, A.B., Suárez, L., et al., (2001) Ataxia with isolated Vitamin E deficiency: Case report and review of the literature. Journal of Pediatric Gastroenterology and Nutrition, 33, 206-210. doi:10.1097/00005176-200108000-00022

[24]   Benomar, A., Yahyaoui, M., Meggouh, F., et al., (2002) Clinical comparison between AVED patients with (744 Del A) mutation and Friedreich ataxia with GAA expansion in 15 Moroccan families. Journal of the Neurological Sciences, 198, 25-29. doi:10.1016/S0022-510X(02)00057-6

[25]   Marzouki, N., Benomar, A., Yahyaoui, M., et al., (2005) Vitamin E deficiency ataxia with (744 Del A) mutation on a-TTP gene: Genetic and clinical peculiarities in Moroccan patients. European Journal of Medical Genetics, 48, 21-28. doi:10.1016/j.ejmg.2005.01.014

[26]   Schurks, M., Glynn, R.J., Rist, P.M., et al., (2010) Effects of Vitamin E on stroke subtypes: Meta-analysis of randomised controlled trials. British Medical Journal, 341, 1-8. doi:10.1136/bmj.c5702

[27]   Argyriou, A.A., Chroni, E., Koutras, A., et al., (2006) Preventing paclitaxel-induced peripheral neuropathy: A phase II trial of Vitamin E supplementation. Journal of Pain and Symptom Management. 3, 237-244. doi:10.1016/j.jpainsymman.2006.03.013

[28]   Pace, A., Giannarelli, D., Galiè, E., et al., (2010) Vitamin E neuroprotection for cisplatin neuropathy: A randomized, placebo-controlled trial. Neurology, 74, 762-766. doi:10.1212/WNL.0b013e3181d5279e

 
 
Top